Abstract 2078P
Background
Chemotherapy-induced nausea and vomiting (CINV) occurs in two arbitrarily defined phases: the acute phase (from 0 to 24 h following chemotherapy (CT) initiation) and the delayed phase (from 24 to 120 h). Almost all antiemetic studies have therefore evaluated efficacy to 120 h after the administration of CT, and the period beyond 120 h is generally perceived to be relatively free of CINV, with some studies reporting continued nausea beyond the delayed phase.
Methods
In July and September of 2022, healthcare providers (HCPs) in Japan were recruited to complete an online quantitative survey. All HCPs were required to work with patients receiving anticancer CT in the hospital setting and have experience selecting, preparing and/or administering antiemetics. As part of this survey responses were collected on whether HCPs had patients who experienced nausea/vomiting (CINV) during Days 5-7 (beyond the delayed phase) after initiation of CT. Responses were also captured by CT regimen; for the physician subset, respondents were grouped by and analyzed only if they were prescribers of the chemotherapy type.
Results
A total of 809 HCPs (174 pharmacists, 102 nurses and 533 physicians) completed the survey. The physician group was comprised of breast surgeons (n = 57), pulmonologists (n = 107), gastroenterologists (n = 74), GI surgeons (89), gynecologists (n = 98), ENTs (n = 54), and oncologists (n = 54). The vast majority of respondents (98%, 93%, and 88% of pharmacists, nurses, and physicians, respectively) indicated they had patients who experienced CINV 5-7 days after CT. Of the HCPs reporting patients with CINV on Days 5-7, the highest proportions were seen for cisplatin, AC and EC chemotherapy regimens (Table). Table: 2078P
Proportions of respondents with patients experiencing CINV on days 5-7 by chemotherapy regimen
CT Regimen | Pharmacists | Nurses | Physician Prescribers |
Cisplatin | 78% | 71% | 80% |
Epirubicin/cyclophosphamide (EC) | 50% | 43% | 43% |
Anthracycline/cyclophosphamide (AC) | 44% | 45% | 42% |
Carboplatin | 37% | 43% | 48% |
Irinotecan | 41% | 37% | 37% |
Oxaliplatin | 36% | 32% | 28% |
Conclusions
This survey highlights a need for continued assessment of CINV beyond the delayed phase after CT to better understand the incidence and to optimize prevention of CINV for the entire period of risk.
Clinical trial identification
Editorial acknowledgement
Jennifer Vanden Burgt.
Legal entity responsible for the study
Helsinn Healthcare.
Funding
Helsinn Healthcare.
Disclosure
F. Scotté: Financial Interests, Personal, Advisory Board: Helsinn Healthcare, Vifor, MSD, Tesaro; Financial Interests, Personal, Financially compensated role: Roche, Amgen, Pfizer, Leo Pharma, Viatris, Mundi Pharma, Clovis Oncology, BMS, Biogaran, Pierre Fabre Oncology, Arrow, GSK. M.S. Aapro: Financial Interests, Personal, Invited Speaker: Amgen, ViforPharma; Financial Interests, Institutional, Other, Grant to SPCC: BMS, ExactSciences, Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Institutional, Invited Speaker, Grant to SPCC: Helsinn; Financial Interests, Institutional, Other, grant to SPCC: Mundipharma, Fresenius Kabi, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Member of Board of Directors: European Cancer Organisation, SIOG, UICC; Financial Interests, Institutional, Member of Board of Directors: SPCC, ALL CAN; Non-Financial Interests, Advisory Role, Confidentiality agreement: Various companies; Non-Financial Interests, Leadership Role: European Cancer Organisation, SPCC, SIOG; Non-Financial Interests, Member: MASCC, SBOC, ASCO; Other, SAB member: European School of Oncology. Y. Takeuchi: Financial Interests, Personal, Full or part-time Employment: Intage Healthcare Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06